JosÃ© A Paramo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7897874/publications.pdf

Version: 2024-02-01

42 papers	1,035 citations	430442 18 h-index	433756 31 g-index
44 all docs	44 docs citations	44 times ranked	1731 citing authors

#	Article	IF	Citations
1	Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfusion, 2013, 11, 585-610.	0.3	108
2	Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis, 2003, 170, 269-276.	0.4	98
3	Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. Journal of Magnetic Resonance Imaging, 2017, 46, 1810-1817.	1.9	73
4	Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis, 2003, 171, 67-73.	0.4	64
5	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/Câ€Xâ€C chemokine receptor 4 axis. Hepatology, 2015, 62, 166-178.	3.6	61
6	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver International, 2015, 35, 1590-1596.	1.9	55
7	Matrix metalloproteinaseâ€10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver International, 2014, 34, e257-70.	1.9	43
8	The Role of Circulating Biomarkers in Peripheral Arterial Disease. International Journal of Molecular Sciences, 2021, 22, 3601.	1.8	40
9	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	2.6	37
10	The CXCR4/SDF1 Axis Improves Muscle Regeneration Through MMP-10 Activity. Stem Cells and Development, 2014, 23, 1417-1427.	1.1	36
11	Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. Journal of Vascular Surgery, 2015, 61, 428-435.	0.6	35
12	Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury. PLoS ONE, 2014, 9, e94370.	1.1	34
13	Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). Journal of Extracellular Vesicles, 2020, 9, 1729646.	5.5	34
14	Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. Nephrology, 2010, 15, 178-183.	0.7	31
15	Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. Atherosclerosis, 2018, 278, 124-134.	0.4	27
16	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. Journal of the American Heart Association, 2017, 6, .	1.6	24
17	Functional MMPâ€10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB Journal, 2015, 29, 960-972.	0.2	19
18	Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease. Journal of Vascular Surgery, 2017, 66, 1527-1533.e1.	0.6	19

#	Article	IF	Citations
19	Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead. Journal of Medicinal Chemistry, 2015, 58, 2465-2488.	2.9	18
20	Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clinical and Translational Oncology, 2005, 7, 150-155.	1.2	15
21	Topical Issues in Venous Thromboembolism. Drugs, 2010, 70, 11-18.	4.9	12
22	Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium. Thrombosis Research, 2018, 170, 1-9.	0.8	12
23	Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3R)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the Prevention and Treatment of Hemorrhage. Journal of Medicinal Chemistry, 2015, 58, 2941-2957.	2.9	11
24	Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. BMC Neurology, 2015, 15, 111.	0.8	11
25	Pulmonary Embolism, Pulmonary Microvascular Thrombosis, or Both in COVID-19?. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093395.	0.7	9
26	Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study. Life, 2021, 11, 414.	1.1	9
27	Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2022, 63, 648-656.	0.8	8
28	PURIFICATION AND CHARACTERIZATION OF A VARIANT OF HUMAN PROTHROMBIN: PROTHROMBIN SEGOVIA. Thrombosis Research, 1997, 85, 465-477.	0.8	7
29	Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 297-308.	0.7	6
30	Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients. Journal of Critical Care, 2019, 51, 117-121.	1.0	5
31	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. Scientific Reports, 2020, 10, 10329.	1.6	5
32	Trombosis microvascular y sus implicaciones clÃ¬nicas. Medicina ClÃ¬nica, 2021, 156, 609-614.	0.3	4
33	Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients. Biomarker Insights, 2007, 1, 165-73.	1.0	3
34	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. European Journal of Haematology, 2016, 97, 128-136.	1.1	2
35	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. ACS Medicinal Chemistry Letters, 2018, 9, 428-433.	1.3	2
36	Integrating Soluble Biomarkers and Imaging Technologies in the Identification of Vulnerable Atherosclerotic Patients. Biomarker Insights, 2006, 1, 117727190600100.	1.0	1

#	Article	IF	Citations
37	SP453MATRIX METALLOPROTEINASE-10 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) AS EARLY PREDICTORS OF NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Nephrology Dialysis Transplantation, 2018, 33, i500-i500.	0.4	1
38	Corrigendum to â€œPreliminary characterisation of the promoter of the human p22phoxgene: Identification of a new polymorphism associated with hypertensionâ€•[FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	1.3	0
39	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. TH Open, 2019, 03, e153-e156.	0.7	0
40	Microvascular thrombosis and clinical implications. Medicina ClÃnica (English Edition), 2021, 156, 609-614.	0.1	0
41	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. Thrombosis and Haemostasis, 2022, 0, .	1.8	0
42	Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms. Life, 2022, 12, 823.	1.1	0